Atrium Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Atrium Therapeutics Inc 's ROA in the second quarter of 2026?
Atrium Therapeutics Inc recorded a cumulative net loss of $-542 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -46.51%.

However, within the Healthcare sector 541 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3893, from total ROA ranking in the first quarter of 2026 at 4533.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-79.48 %	-79.96 %	25.36 %	30.19 %	2.81 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-542	-680	-779	-550	-456
Return On Assets (TTM)	-46.51 %	-47.26 %	-45.02 %	-33.72 %	-30.25 %
RNA's Total Ranking	# 3893	# 4533	# 3824	# 3788	# 3726
Total Assets (TTM) in million	281	292	1,958	2,134	1,367
Seq. Total Assets Change	-4.05 %	-85.07 %	-8.25 %	56.11 %	-6.27 %
Seq. Net Income Change	-	-	-	-	-

RNA's 5 Years Annual ROA >> Back to RNA Management Effectiveness >> Compare RNA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 229
Sector	# 542
Overall	# 3853

Return On Assets Statistics
High	Average	Low
-2.15 %	-29.94 %	-47.24 %
(Dec 31 2020)		(Mar 31 2026)

Financial Statements
Atrium Therapeutics Inc 's Assets	$ 281 million	RNA's Balance sheet
Atrium Therapeutics Inc 's Income	$ -20 million	Quarterly RNA's Income Statement
RNA's Income by Division		See RNA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	25.36 %	148.5 %	-1.6 %	49.4 %	28.06 %
Total Assets in million	1,958	1,562	629	639	428
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-685	-322	-212	-174	-118
Annual Return On Assets	-34.96 %	-20.63 %	-33.76 %	-27.24 %	-27.6 %

RNA's 5 Years Annual ROA >> Back to RNA Management Effectiveness >> Compare RNA ROA to its Competitors

More Return On Assets Ratios
RNA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RNA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RNA's Competitors
Subscribers only: Roa for Atrium Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for RNA's Customers

You may also want to know
RNA's Roi	RNA's Inventory Turnover Ratio	RNA's Growth Rates	RNA's Dividend Comparisons
	RNA's Profitability Ratios	RNA's Asset Turnover Ratio	RNA's Dividend Growth
RNA's Roe	RNA's Valuation Ratios	RNA's Financial Strength Ratios	RNA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-03T12:12:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.